Valuation: Monte Rosa Therapeutics, Inc.

Market Cap 925M 825M 763M 692M 1.3B 87.79B 1.31B 9.18B 3.63B 46.01B 3.47B 3.4B 145B P/E 2026 *
-7.41x
P/E 2027 * -5.82x
Enterprise Value 607M 542M 501M 454M 851M 57.64B 863M 6.02B 2.38B 30.21B 2.28B 2.23B 95.25B EV / Sales 2026 *
8.88x
EV / Sales 2027 * 7.64x
Free-Float
99.44%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Monte Rosa Therapeutics, Inc.

1 day-2.43%
1 week+11.29%
Current month-9.14%
1 month-7.51%
3 months-52.41%
6 months-45.22%
Current year-30.87%
1 week 9.76
Extreme 9.76
11.74
1 month 9.68
Extreme 9.68
12.26
Current year 9.68
Extreme 9.68
25.77
1 year 9.68
Extreme 9.68
25.77
3 years 2.44
Extreme 2.44
25.77
5 years 2.44
Extreme 2.44
27.56
10 years 2.44
Extreme 2.44
45.56
Manager TitleAgeSince
Chief Executive Officer 55 31/12/2019
Chief Tech/Sci/R&D Officer - 16/03/2026
Chief Operating Officer 54 28/02/2021
Director TitleAgeSince
Director/Board Member 55 31/12/2019
Director/Board Member 49 31/03/2020
Director/Board Member 57 31/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
05/10/26 Sell

Controller/Auditor

-13 0.0000%
16/07/26 Sell

Chief Executive Officer

-9,500 0.0112%
15/07/26 Exercice

Chief Operating Officer

13,053 0.0155%
Change 5-day change 1-year change 3-year change Capi.($)
-2.43%+11.29%-2.69%+320.16% 925M
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average +0.00%+3.30%+43.00%+158.81% 38.4B
Weighted average by Cap. +0.38%+2.75%+45.90%+143.26%

Financials

2026 *2027 *
Net sales 68.35M 60.98M 56.38M 51.11M 95.77M 6.49B 97.16M 678M 268M 3.4B 257M 251M 10.72B 64.61M 57.64M 53.3M 48.31M 90.53M 6.13B 91.85M 641M 253M 3.21B 242M 237M 10.14B
Net income -148M -132M -122M -111M -207M -14.04B -210M -1.47B -580M -7.36B -555M -543M -23.2B -196M -175M -162M -147M -275M -18.65B -279M -1.95B -771M -9.77B -737M -722M -30.82B
Net Debt -318M -283M -262M -238M -445M -30.16B -452M -3.15B -1.25B -15.81B -1.19B -1.17B -49.84B -431M -384M -355M -322M -604M -40.91B -613M -4.28B -1.69B -21.44B -1.62B -1.58B -67.6B
Projected Income Statement - Annual - Monte Rosa Therapeutics, Inc.
Logo Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Employees
173
Date Price Change Volume
23/10/26 US$10.84 -2.43% 817,827
22/10/26 US$11.11 -0.98% 1,284,514
21/10/26 US$11.22 -1.23% 1,080,022
20/10/26 US$11.36 +6.57% 1,865,618
19/10/26 US$10.66 +9.45% 1,925,835
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Monte Rosa Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
10.84USD
Average target price
26.88USD
Spread / Average Target
+147.92%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Monte Rosa Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. GLUE Stock